Data-driven
precision medicine
Bringing the power of data and artificial intelligence to healthcare
With the power of AI, we now have the ability to
-
ACCELERATE
the discovery of novel targets
-
PREDICT
the effectiveness of treatments
-
IDENTIFY
potentially life-saving clinical trials
-
DIAGNOSE
multiple diseases earlier
Explore Tempus
We can assist pharmaceutical and biotech companies with better drug development.
Learn MoreWe have built a proprietary Platform to make data accessible and deploy AI at scale
Learn MoreOur Science
Through our scientific publications and research projects, we are accelerating and transforming personalized patient care.
View All Publications
Nature Biotechnology Study Reveals that Tempus’ xT Platform Increases Cancer Patients’ Personalized Therapeutic Opportunities
Extensive molecular profiling combined with clinical data identifies targeted therapies and clinical trials for a large proportion of cancer patients, and paired tumor/normal plus transcriptome sequencing outperforms tumor-only DNA panel testing.
A Pan-cancer Organoid Platform for Precision Medicine
Showcasing a robust pan-cancer tumor organoid (TO) platform, revealing genomic/transcriptome fidelity of TO culture from >1,000 patients. We demonstrate a neural-network-based high-throughput approach for label-free, light-microscopy-based drug assays capable of predicting patient-specific heterogeneity in drug responses with applicability across solid cancers.
Validation of a Liquid Biopsy Assay with Molecular and Clinical Profiling of Circulating Tumor DNA
Actionable variants would have been missed if only solid tumor or liquid biopsy tests were performed. Thus, we believe that liquid biopsies provide value to patients when used in combination with standard tissue genotyping.
Tempus and Kronos Bio establish a multi-year collaboration to leverage Tempus’ platform
Tempus and Kronos Bio signed a strategic collaboration that provides Kronos Bio with access to Tempus’ real-world genomic and transcriptomic data and data analytics tools to advance its current and future oncology therapeutic portfolio.
READ PRESS RELEASEEric Lefkofsky joins the Washington Post’s “Chasing Cancer” series
The Tempus CEO discusses the state of precision medicine with reporter Yasmeen Abutaleb.
WATCH HERETempus introduces the DPYD predictive diagnostic test to its growing collection of algorithms
The new predictive test assesses for relevant mutations in the DPYD gene and helps physicians better identify patients at potential risk for toxicity to certain chemotherapies.
READ PRESS RELEASEThis is data-driven precision medicine
This is the future of healthcare.